1. Generics Bulletin
  3. >>Generics

Glenmark Launches Tiotropium DPI In Spain

As Company Looks At Several Other European Markets For Tavulus

 
• By Akriti Seth

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

Spain
Glenmark launches tiotropium bromide dry powder inhaler under the brand name Tavulus in Spain • Source: Alamy

Glenmark Pharmaceuticals Limited has launched its tiotropium bromide dry powder inhaler under the brand name Tavulus in Spain. The Indian company’s launch of the bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler in Spain follows its recent launch in the UK under the name Tiogiva (see sidebar).

With the Spanish launch, Glenmark said it “became one of the first companies to launch a bioequivalent version of the dry powder inhaler” in the UK and in Europe, noting that the launch in Spain was part of Glenmark’s wider strategic exclusive in-licensing arrangement to market tiotropium DPI in Western Europe

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.